Q2 2026 InfuSystem Holdings Inc Earnings Call Transcript
Key Points
- InfuSystems Holdings Inc (INFU) achieved a new quarterly revenue record of $36.9 million, a 2.6% increase year-over-year on a GAAP basis and a 7.5% increase on a non-GAAP pro forma basis.
- The company's oncology business surpassed the $20 million quarterly revenue mark for the first time, growing 6.4% year-over-year and serving 18 of the top 20 U.S. hospital systems.
- Wound care revenue surged 154% year-over-year, driven by the successful launch and expansion of pneumatic compression devices and adjustable compression wraps for lymphedema patients.
- Adjusted EBITDA increased 7.6% to $8.6 million, with the margin expanding by over 1% to 23.4%, driven by the GE Healthcare contract restructuring and other operational improvements.
- The company maintains a strong balance sheet with $55.2 million in available liquidity and a conservative leverage profile of 0.61 times trailing 12-month adjusted EBITDA, supporting future investments and acquisitions.
- Gross margin expanded significantly to 58% from 55.2% in the prior year, driven by an 8.3% improvement in Device Solutions gross margin due to the GE restructuring and procurement initiatives.
- GAAP revenue growth was impacted by the restructuring of the GE Healthcare contract, which reduced revenue by $1.6 million during the quarter.
- Device Solutions revenue declined by 16.1% year-over-year, primarily due to the GE contract restructuring and a 49% decline in equipment sales from a large customer buyout last year.
- Patient services gross margin declined to 61.8% from 64.2% in the prior year, due to a larger mix of lower-margin wound care revenue and increased pump maintenance costs.
- Selling and marketing expenses increased 10.5% and G&A expenses rose 7.2%, reflecting higher stock-based compensation, wage inflation, healthcare costs, and investments to support growth.
- The company continues to incur costs related to its ERP system implementation, though spending has tapered down sequentially, it remains a drag on profitability.
- The company expects annual revenue to be $7.1 million lower due to the GE Healthcare contract restructuring, and it has not provided a specific timeframe for achieving its long-term adjusted EBITDA margin target of 22% to 25%.
Good morning and welcome to the Infuse System Holdings, Inc. Reports Second Quarter.
Fiscal year 2026 financial results conference call. (Operator Instructions)
I would now like to turn the conference over to Glenn Akselrod, Investor Relations. Please go ahead.
Good morning, and thank you for joining us today to review Infuse Systems' second quarter 2026 financial results ended June 30th, 2026. With us today on the call are Carrie Lachance, Chief Executive Officer, and Barry Steele, Chief Financial Officer. After the conclusion of today's prepared remarks, we will open the call for questions.
Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of Infusystem during this conference call constitute forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1,995. Except for statements of historical fact, this conference call may contain forward-looking statements that involve
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
